<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interpretation of HIV drug resistance testing</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interpretation of HIV drug resistance testing</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Interpretation of HIV drug resistance testing</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Kozal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 17, 2019.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Managing patients with HIV drug resistance has become less common. Advances in drug development have allowed for more potent antiretroviral therapy (ART) regimens that are easier to take, resulting in fewer patients who develop drug-resistant strains of HIV [<a href="#rid1">1</a>]. However, there remains a subset of patients infected with drug-resistant variants, which can challenge an HIV clinician. </p><p>While resistance mutation patterns can be complex, there are basic principles that underlie effective utilization of resistance data. This topic will review the resistance patterns found in association with different antiretroviral agents and describe how that knowledge can impact selection of an appropriate treatment regimen in patients with virologic failure [<a href="#rid2">2</a>]. The details in this topic refer mainly to resistance patterns seen with HIV subtype B, which is the most prevalent clade in the United States, Europe, Japan, Thailand, and Australia. </p><p>Topic reviews that discuss the different types of resistance tests and provide detailed guidance on selecting an ART regimen are found elsewhere. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays"</a> and  <a class="medical medical_review" href="/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a> and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a> and  <a class="medical medical_review" href="/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p class="headingAnchor" id="H2548093486"><span class="h1">FACTORS CONTRIBUTING TO RESISTANCE</span><span class="headingEndMark"> — </span>Multiple factors influence the development of HIV drug resistance, including the biology of HIV, genetic barriers to resistance, regimen potency, pharmacokinetics of antiretroviral drugs, and medication adherence. Drug-resistant mutations can predate the initiation of a specific drug regimen [<a href="#rid3">3</a>] or can develop when viral replication continues in the face of ongoing drug pressure.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV biology</strong> – HIV infection is characterized by high rates of replication, with more than 10<sup>9</sup> virions produced daily [<a href="#rid4">4</a>]. In addition, HIV reverse transcriptase, which is responsible for replicating the viral genome, is error-prone. The combination of the high rate of replication and the frequent introduction of mutations during each round of replication leads to the occurrence of randomly generated mutations, some of which confer drug resistance [<a href="#rid5">5</a>]. The resulting population of genetically related, but distinct, HIV variants in a patient is referred to as a "quasispecies."</p><p></p><p class="bulletIndent1">Viruses with spontaneous mutations are often defective and incapable of replication. However, some mutations can persist in proviral HIV DNA in resting memory cells if the mutant virus has a selective growth advantage over wild-type virus [<a href="#rid6">6</a>]. If viral replication is not fully suppressed by an antiretroviral regimen, these mutants can reemerge. Depending on their level of drug resistance, these mutants can either cause overt virologic failure or become more drug resistant by the gradual accumulation of additional resistance mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic barriers to resistance</strong> – HIV can develop high-level resistance to some drugs with only a single mutation, while other drugs require multiple mutations. Drugs in the former situation are referred to as having a "low genetic barrier" to resistance. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p></p><p class="bulletIndent1">Several antiretroviral agents have a low genetic barrier to resistance. These include the nucleoside reverse transcriptase inhibitor (NRTI) <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> (and the closely related agent <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>), the non-nucleoside reverse transcriptase inhibitors (NNRTIs) <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, and the integrase strand transfer inhibitors (INSTIs) <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>. </p><p></p><p class="bulletIndent1">By contrast, a high resistance barrier is seen in the protease inhibitor (PI) class and with the INSTIs <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and bictegravir. Resistance to these agents usually requires the accumulation of multiple mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen potency</strong> – The potency of an antiretroviral regimen is a crucial determinant of viral load suppression. If the viral load is not fully suppressed, continued virus replication in the presence of drug can lead to the accumulation of mutations. This can lead to the development of viral resistance, even to drugs with a high genetic barrier to resistance. As an example, unboosted PIs, which are no longer recommended, had a high genetic barrier to resistance but achieved low serum trough concentrations; thus, virus could continue to replicate and accumulate mutations that led to high levels of resistance. This problem can be offset by the use of pharmacokinetic "boosting" with <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'</a>.)</p><p></p><p class="bulletIndent1">This principle was illustrated in a trial in which 653 treatment-naïve patients were randomly assigned to receive <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> in combination with a PI, either <a class="drug drug_general" data-topicid="9982" href="/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> or <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a> (a less potent PI) [<a href="#rid7">7</a>]. After 48 weeks of follow-up, the emergence of resistance and virologic failure was more common in patients in the nelfinavir arm compared with the lopinavir arm. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetic factors</strong> – There are several ways that pharmacokinetic factors can lead to drug resistance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low serum concentrations</strong> – Low serum concentrations of an antiretroviral agent can be seen as a result of drug interactions, poor absorption, or secondary to the pharmacokinetics of a specific agent (eg, unboosted PIs). Continued virus replication in the presence of drug can lead to the accumulation of mutations. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Varying half-lives</strong> – Resistance can result when individual components of an HIV antiretroviral regimen have varying plasma half-lives. In this case, discontinuation of the regimen can lead to functional monotherapy. As an example, when the combination of <a class="drug drug_general" data-topicid="8858" href="/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a> is discontinued, the half-life of <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> is longer than the half-lives of <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> or <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>, and the patient may be at risk of developing efavirenz resistance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic factors</strong> – Pharmacokinetic profiles can vary significantly in different patient populations. This pharmacokinetic variability was well illustrated in a study of 152 patients who were receiving <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, which is metabolized primarily by cytochrome p450 2B6 isoenzymes [<a href="#rid8">8</a>]. A G-to-T polymorphism at position 516 of CYP2B6 was associated with higher plasma efavirenz concentrations and slower clearance [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1">Therapeutic drug monitoring (TDM) is of theoretical utility to ensure that there is adequate drug exposure [<a href="#rid3">3</a>]. However, the role of TDM in clinical practice remains controversial because of the lack of prospective studies demonstrating that TDM improves clinical outcome in patients with drug-resistant HIV. In addition, plasma NRTI concentrations are not thought to be as important clinically due to the intracellular location of their active forms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication adherence</strong> – Nonadherence to antiretroviral therapy is closely associated with incomplete viral suppression and the development of drug-resistant HIV variants [<a href="#rid10">10</a>]. The relationship between adherence and drug resistance is complex and influenced by drug potency, pill burden, and pharmacokinetics [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy", section on 'Nonadherence'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">BASIC TERMINOLOGY</span><span class="headingEndMark"> — </span>This section defines the terms that are used when describing drug resistance. </p><p class="headingAnchor" id="H19102023"><span class="h2">Wild-type virus</span><span class="headingEndMark"> — </span>"Wild-type" virus refers to the original parent virus that was predominant prior to the use of antiretroviral medications. A patient may become infected by either a wild-type or a resistant strain. As there are many HIV viral variants that are considered "wild type," all are compared to a reference strain in laboratories that perform drug resistance testing.</p><p class="headingAnchor" id="H19102152"><span class="h2">Viral fitness</span><span class="headingEndMark"> — </span>Viral fitness generally refers to the ability of one virus to out-compete a second virus in a defined environment [<a href="#rid6">6,13</a>]. In general, wild-type virus replicates more efficiently (ie, is more "fit") in cell culture than resistant virus and overgrows mutant variants in the absence of drug selection pressure.</p><p>In the setting of drug therapy, drug-resistant virus is selected, despite that it is less fit in the absence of drug [<a href="#rid6">6</a>]. Viral variants with reduced fitness may be less pathogenic, although studies examining the correlation of HIV replication fitness with clinical outcome have not given consistent results [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H19102159"><span class="h2">Replication capacity</span><span class="headingEndMark"> — </span>Replication capacity refers to the ability of the virus to replicate in comparison to another reference virus. Replication capacity can either decrease or increase in the presence of certain mutations. </p><p>In the early era of potent antiretroviral therapy, some patients demonstrated transient immunologic benefit despite ongoing viremia [<a href="#rid15">15,16</a>]. This may have been related to the selection of a "less fit" drug-resistant virus population. Viral fitness is inferred through measurement of replication capacity, which can be obtained from one phenotypic assay, PhenoSense HIV (Monogram Biosciences, Clinical Reference Laboratory). (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays"</a>.)</p><p>However, the primary goal is always complete viral suppression, which is associated with durable immunologic benefit. Viral suppression is usually achievable with currently available antiretroviral medications, even among patients with multi-class drug resistance [<a href="#rid3">3,17</a>]. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H19102011"><span class="h2">Mutational patterns</span><span class="headingEndMark"> — </span>By convention, mutations are indicated by a codon number preceded by a letter indicating the consensus amino acid in wild-type (drug-susceptible) virus and followed by a letter indicating the amino acid substitution in the mutant virus. For example, "M184V" indicates that valine has been substituted for methionine at amino acid codon 184 in the reverse transcriptase enzyme. The notation "M184M/V" indicates the presence of a mixture of wild-type (M) and mutant (V) virus. </p><p class="headingAnchor" id="H5"><span class="h2">Signature mutation</span><span class="headingEndMark"> — </span>A "signature mutation" is a mutation that is typically associated with resistance to a particular drug. As an example, the K103N mutation is the signature mutation for <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Other signature mutations are described below. (See <a class="local">'Interpretation of resistance mutations'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Cross-resistance</span><span class="headingEndMark"> — </span>The term "cross-resistance" refers to resistance to drugs other than the drug that selected the mutation(s). As examples, the M184V mutation associated with <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> confers cross-resistance to the related drug <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, and the K103N mutation selected by the NNRTIs <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> and <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> confer cross-resistance to each other. However, a specific mutation may not cause cross-resistance to all agents within a class. Although virus expressing the K103N is resistant to nevirapine and efavirenz, other NNRTIs, such as <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, maintain activity if there are no other additional NNRTI mutations. Similarly, a mutation at position Y143 can confer resistance to <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> but has little effect on <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> susceptibility. (See <a class="local">'Non-nucleoside reverse transcriptase inhibitors'</a> below and <a class="local">'Integrase strand transfer inhibitors'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Hypersusceptibility</span><span class="headingEndMark"> — </span>On occasion, resistance to one drug can lead to increased susceptibility, or hypersusceptibility, to another drug. For example, the M184V mutation that confers <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> resistance causes hypersusceptibility to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and tenofovir compared with wild-type virus [<a href="#rid18">18</a>]. Another example is the TAM T215Y, which is associated with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> hypersusceptibility when present [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Accessory mutations</span><span class="headingEndMark"> — </span>When HIV continues to replicate, additional minor mutations may accumulate over time. These accessory or secondary mutations further increase drug resistance or can compensate for the loss of viral fitness induced by the primary mutations. Thus, it is important to switch antiretroviral therapy rather than expose a patient with ongoing viremia to the same drugs in order to avoid the accumulation of additional mutations [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Management of patients with incomplete viral suppression'</a>.)</p><p class="headingAnchor" id="H1930849959"><span class="h2">Polymorphisms</span><span class="headingEndMark"> — </span>In a given sample, some amino acid changes within a viral gene may be identified that differ from the consensus amino acid sequence in wild-type virus. These amino acid substitutions are often termed "polymorphisms" and do not on their own confer phenotypic or in vitro resistance to a particular antiretroviral agent [<a href="#rid6">6</a>]. Resistance interpretations should indicate drug susceptibility when these polymorphisms are identified.</p><p class="headingAnchor" id="H2378582506"><span class="h1">INTERPRETATION OF RESISTANCE MUTATIONS</span><span class="headingEndMark"> — </span>Because our understanding of how best to interpret resistance testing continues to evolve, a specialist experienced in the management of HIV infection and interpretation of drug resistance testing should be consulted. Patterns of mutations can be complex, and interpretations can change over time as more information is obtained regarding the relationship between drug resistance mutations and response to therapy. </p><p class="headingAnchor" id="H896707310"><span class="h2">Resistance testing</span><span class="headingEndMark"> — </span>Resistance testing is important to help guide treatment decisions in both treatment-naïve and treatment-experienced patients [<a href="#rid20">20-22</a>]. Drug-resistant mutations may be related to transmission of a drug-resistant virus at the time of initial infection or may arise due to continued virus replication in the presence of drug (eg, patients who do not take their regimen as prescribed). A discussion of HIV drug resistance assays is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays"</a>.)</p><p>In treatment-experienced patients with virologic failure, it is preferable to obtain resistance testing while the patient is taking antiretroviral therapy (ART) or is within weeks of discontinuing treatment; however this might not be possible in patients who are nonadherent to their regimen. In the absence of drug pressure, the wild-type HIV strain may become dominant. Although some mutations may persist off ART [<a href="#rid23">23</a>], the results can be misleading if drug resistance testing is performed when patients are not receiving ART. Similarly, resistance testing is less reliable at detecting resistance to classes of drugs no longer being taken. These limitations emphasize the importance of taking a complete medication history. (See  <a class="medical medical_review" href="/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Nucleoside reverse transcriptase inhibitors</span><span class="headingEndMark"> — </span>Any nucleoside reverse transcriptase inhibitor (NRTI) can select for resistance mutations when used in a nonsuppressive regimen. The specific mutation pattern may be associated with varying degrees of NRTI cross-resistance. In general, a single mutation can lead to resistance to <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, tenofovir, or <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, whereas resistance to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> usually requires multiple mutations. A summary of NRTI resistance mutations can be found on the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iasusa.org%2Fresources%2Fhiv-drug-resistance-mutations%2F&amp;token=E7Z%2Fs9z7wwGq%2BhpQ5GnDQittikdG9qKtPgjQLTll85GEDXV87h%2FzbaX3Cw8XVWHVmFDYGBBQjVSfdRGD4420mq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3772" target="_blank">International Antiviral Society - USA</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=3772" target="_blank">Stanford HIV Drug Resistance Database</a> websites, which are updated regularly [<a href="#rid24">24-27</a>]. </p><p class="headingAnchor" id="H16"><span class="h3">Zidovudine and stavudine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> are thymidine analogs, which share common resistance patterns. Although these agents are no longer recommended as first-line therapy because of their toxicity [<a href="#rid28">28-30</a>], it is important to understand their effect on drug resistance in patients who were previously exposed to these agents. </p><p>Common resistance mutations include M41L, L210W, T215Y, D67N, K70R, and K219Q/E/N [<a href="#rid31">31</a>]. These substitutions are referred to as "thymidine analog mutations" (TAMs) because they are selected by the two thymidine analogs (<a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a>). Regimens containing a thymidine analog can select for TAMs and additional mutations, including 44D/A, 118I, 207D/E, 208Y.</p><p>TAMs typically emerge via one of two "pathways":</p><p class="bulletIndent1"><span class="glyph">●</span>Pattern 1 includes the M41L, L210W, and T215Y mutations.</p><p class="bulletIndent1"><span class="glyph">●</span>Pattern 2 involves the D67N, K70R, and K219Q/E/N mutations [<a href="#rid32">32,33</a>].</p><p></p><p>However, there can be mixtures of both patterns present in some patients [<a href="#rid32">32,33</a>]. TAMs continue to accumulate when patients continue failing ART regimens.</p><p>The first TAM pathway listed above confers cross-resistance to all NRTIs and the nucleotide analog, tenofovir [<a href="#rid24">24,34,35</a>]. The second pathway confers resistance primarily to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> but causes less cross-resistance to <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a>, and tenofovir. Since zidovudine and stavudine are both thymidine analogs, resistance to zidovudine results in cross-resistance to stavudine, and vice versa. </p><p>TAMs are uncommon with early failure of a thymidine analog-containing regimen. At least three TAMs are usually required before virologic activity of <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> or <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> is completely lost. However, continuation of a thymidine analog-containing regimen in the presence of ongoing viremia will result in accumulation of additional TAMs, leading to greater resistance and NRTI cross-resistance [<a href="#rid36">36-38</a>]. (See <a class="local">'Accessory mutations'</a> above and <a class="local">'Multinucleoside resistance mutations'</a> below.) </p><p>In the case of multiple TAMs, phenotypic testing may be helpful for determining whether any NRTIs are likely to have partial activity [<a href="#rid39">39</a>]. However, the use of fully active agents is preferred whenever feasible; extensive NRTI resistance may require the use of an ART regimen that includes a combination of agents from other drug classes. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Lamivudine and emtricitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">Lamivudine</a> and <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> are NRTIs with a low genetic barrier to resistance. Lamivudine and emtricitabine both select for the M184V mutation. This is the most prevalent NRTI-associated mutation seen in treated patients, in part because of its widespread use. It is often the first mutation to appear [<a href="#rid39">39</a>].</p><p>M184V (as well as the less common M184I mutation) causes high-level in vitro resistance to both <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>. It also causes a modest decrease in susceptibility to <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a> [<a href="#rid40">40</a>] and <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a> [<a href="#rid41">41</a>]. However, M184V confers hypersusceptibility to tenofovir, <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> and, therefore, partially reverses TAM-mediated resistance to these drugs [<a href="#rid36">36</a>]. (See <a class="local">'Hypersusceptibility'</a> above and <a class="local">'Zidovudine and stavudine'</a> above.) </p><p>The M184V mutation also leads to decreased replication capacity of HIV [<a href="#rid42">42</a>]. Thus, a viral isolate with this mutation is "less fit" than wild-type virus [<a href="#rid43">43</a>]. Continuation of either <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, with maintenance of the M184V mutation, leads to a persistent mean 0.5 log decrease in viral load from baseline. (See <a class="local">'Replication capacity'</a> above.)</p><p>Some clinicians maintain <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> in a regimen despite the presence of the M184V mutation because of the safety, tolerability, and residual partial virologic activity of these drugs, as well as the beneficial effect on susceptibility to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a>, and tenofovir [<a href="#rid44">44</a>]. This is probably most important in regimens containing NRTIs, especially tenofovir. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Tenofovir</span><span class="headingEndMark"> — </span>Tenofovir is available as one of two tenofovir prodrugs: <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) and <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF). Resistance considerations are generally the same for both agents, although the higher intracellular tenofovir concentrations achieved with TAF may give it greater activity against some NRTI-resistant viruses. A more detailed review of these agents is found elsewhere. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir'</a>.)</p><p>K65R is the signature mutation associated with tenofovir resistance [<a href="#rid45">45</a>]. The overall prevalence of the K65R mutation is low. However, when it occurs, it confers significant cross-resistance to <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, and <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a> [<a href="#rid46">46</a>]. By contrast, the K65R mutation induces hypersusceptibility to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> [<a href="#rid47">47</a>], similar to that seen with the M184V mutation. (See <a class="local">'Lamivudine and emtricitabine'</a> above.) </p><p>First-line tenofovir failure has also been associated with other less common mutations at positions K70E and Y115F [<a href="#rid48">48,49</a>]. In addition, tenofovir resistance can be mediated by the presence of multiple TAMs. TAMs are selected by the two thymidine analogs (<a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a>) and are discussed above. (See <a class="local">'Zidovudine and stavudine'</a> above.)</p><p class="headingAnchor" id="H25"><span class="h3">Abacavir</span><span class="headingEndMark"> — </span>The common mutation for <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a> is L74V [<a href="#rid50">50,51</a>]. Less commonly, abacavir selects for other mutations, including K65R, Y115F, and M184V. When L74V is present in combination with M184V, there is further loss of susceptibility to abacavir. However, the presence of both mutations increases susceptibility to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and tenofovir [<a href="#rid47">47</a>]. In addition, L74V mutant isolates are less fit than wild-type virus [<a href="#rid52">52</a>]. (See <a class="local">'Viral fitness'</a> above.)</p><p>This same resistance pattern is seen with <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a>, an NRTI that is no longer used because of its toxicity. (See  <a class="medical medical_review" href="/d/html/3765.html" rel="external">"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors"</a>.)</p><p class="headingAnchor" id="H28"><span class="h3">Multinucleoside resistance mutations</span><span class="headingEndMark"> — </span>While the most common cause of broad NRTI cross-resistance is the combination of multiple TAMs with M184V [<a href="#rid36">36</a>], two other resistance patterns can also lead to significant NRTI cross-resistance:</p><p class="bulletIndent1"><span class="glyph">●</span>The Q151M complex is associated with resistance to all NRTIs, with the least effect on tenofovir.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The T69 insertion mutation causes resistance to all NRTIs, including tenofovir, when this mutation is accompanied by one or more TAMs at codons 41, 210, or 215.</p><p></p><p>These mutations are usually selected by older NRTI combinations that included <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a> plus either <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> or <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a>. When these mutations are present, the use of an NRTI-sparing regimen may be considered. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Non-nucleoside reverse transcriptase inhibitors</span><span class="headingEndMark"> — </span>The non-nucleoside reverse transcriptase inhibitors (NNRTIs) <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> have a low genetic barrier to resistance compared with protease inhibitors (PIs) and the integrase strand transfer inhibitors (INSTI) <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and bictegravir. <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> is a newer NNRTI approved for use in antiretroviral-naïve HIV-1-infected persons [<a href="#rid53">53,54</a>]. <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">Etravirine</a>, which is used in salvage regimens for patients with drug-resistant virus, has a higher resistance barrier and may be active against some efavirenz- and nevirapine-resistant viruses [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'NNRTI-containing regimens'</a>.)</p><p class="headingAnchor" id="H4262381228"><span class="h3">Efavirenz and nevirapine</span><span class="headingEndMark"> — </span>Initial NNRTI resistance mutations tend to emerge quickly in patients with detectable viremia during NNRTI-based therapy. The most common mutations seen in association with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> or <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> are K103N and Y181C [<a href="#rid56">56</a>]. There is significant cross-resistance between those two agents [<a href="#rid34">34</a>]. As a result, selection of one of these single point mutations (eg, Y181C or K103N) confers loss of activity to both drugs [<a href="#rid57">57</a>]. </p><p>K103N is selected by <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> more frequently than by <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>; Y181C is selected more commonly by nevirapine when <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> is not coadministered. Although efavirenz may appear phenotypically active in the presence of Y181C [<a href="#rid57">57</a>], the use of efavirenz after the emergence of the Y181C mutation on nevirapine leads to the rapid development of resistance and virologic failure [<a href="#rid58">58</a>].</p><p><a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">Efavirenz</a> and <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> may also select Y188L, which confers high-level resistance to some NNRTIs when present as a single mutation. Other common mutations selected by these NNRTIs include: L100I, V106A, G190S/A, and M230L. Accumulation of two or more of these common mutations is associated with broad NNRTI class resistance. Thus, first-generation NNRTIs should be discontinued in patients experiencing virologic failure and documented resistance. Maintaining NNRTI therapy in viremic patients on either efavirenz or nevirapine risks accumulation of further NNRTI resistance mutations, which may reduce the utility of <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a>. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Management of patients with incomplete viral suppression'</a>.)</p><p class="headingAnchor" id="H1768357924"><span class="h3">Rilpivirine</span><span class="headingEndMark"> — </span>In clinical trials that have evaluated the efficacy of <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> in treatment-naïve patients, virologic failure was associated with the emergence of the following resistance-associated mutations: K101E, V189I, Y181C, V90I, H221Y, and E138K [<a href="#rid59">59,60</a>]. E138K, the most frequently observed mutation, is a mutation that by itself causes high-level rilpivirine resistance, as well as potential low-level resistance to other NNRTIs [<a href="#rid24">24,61,62</a>].</p><p>In studies in which <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> was given with <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> or <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, the E138K mutation was most often seen in association with the NRTI mutation M184I or, less commonly, with M184V [<a href="#rid59">59,60,63</a>]. Although M184I/V mutations are associated with a decline in replication capacity, the coexistence of the E138K mutation appears to restore viral fitness [<a href="#rid63">63</a>], particularly when found in combination with M184I [<a href="#rid64">64</a>]. (See <a class="local">'Viral fitness'</a> above.)</p><p class="headingAnchor" id="H381598135"><span class="h3">Doravirine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> was approved by the US Food and Drug Administration (FDA) in 2018 [<a href="#rid54">54</a>]. In clinical trials, the most frequent patterns of mutations conferring high-level resistance involved changes at codon V106 in combination with other known NNRTI resistance substitutions (eg, V106A/M with changes at F227C, Y188L, and Y318F) [<a href="#rid24">24,53,54</a>]. In addition, other NNRTI mutations (eg, G190E/Q and M230L) can confer high-level resistance to the drug [<a href="#rid24">24,54,65</a>]. In an analysis of NNRTI cross-resistance, clinical isolates demonstrated resistance to doravirine when Y188L was identified, alone or in combination with K103N or V106I. Also, the NNRTI mutation combination of G190A and F227L, or E138K in combination with Y181C and M230L, showed greater than 100-fold reduced susceptibility to doravirine [<a href="#rid24">24,54,65</a>]. A better understanding of the most common clinically emergent doravirine resistance profiles will likely be forthcoming once the drug has been used more extensively.</p><p class="headingAnchor" id="H3804787626"><span class="h3">Etravirine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">Etravirine</a> is an NNRTI with activity against a large proportion of NNRTI-resistant viruses isolated from patients with virologic failure on <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> or <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a> [<a href="#rid66">66</a>]. The K103N mutation, which is the most common mutation associated with efavirenz failure, does not cause cross-resistance to etravirine. However, the presence of other NNRTI-associated mutations may affect etravirine potency, as noted above [<a href="#rid67">67</a>]. There are no clinical data on the use of etravirine after virologic failure on <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>. </p><p>The likelihood that <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> will be active against a particular virus can be determined by the presence of specific mutations. A summary of NNRTI resistance mutations can be found on the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iasusa.org%2Fresources%2Fhiv-drug-resistance-mutations%2F&amp;token=E7Z%2Fs9z7wwGq%2BhpQ5GnDQittikdG9qKtPgjQLTll85GEDXV87h%2FzbaX3Cw8XVWHVmFDYGBBQjVSfdRGD4420mq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3772" target="_blank">International Antiviral Society - USA</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=3772" target="_blank">Stanford HIV Drug Resistance Database</a> websites [<a href="#rid24">24,25</a>].</p><p>A retrospective analysis from the DUET trials identified a number of mutations that may diminish response to <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a>, including V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V/Y, and G190S/A [<a href="#rid67">67</a>]. An increased number of mutations was correlated with a declining treatment response. In addition, although no single mutation led to high-level resistance to etravirine, some mutations (eg, those at codon 181) led to "intermediate" level resistance and appeared to have a significant negative impact on etravirine susceptibility and activity. </p><p>Phenotypic drug resistance testing is helpful in determining the residual activity of <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> when multiple mutations are found on genotypic testing. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays", section on 'Phenotypic resistance assays'</a>.) </p><p class="headingAnchor" id="H33"><span class="h2">Protease inhibitors</span><span class="headingEndMark"> — </span>Protease inhibitors (PIs) are almost always given in combination with <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> or low-dose <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>. These boosting agents are used to increase serum trough concentrations of the parent drug. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'</a>.)</p><p>Pharmacologically boosted PIs achieve high serum concentrations and have a high genetic barrier to resistance; therefore, decreased drug susceptibility generally requires the accumulation of multiple mutations. When boosted PIs are used by patients without preexisting PI resistance, treatment failure is rarely associated with PI resistance. (See  <a class="medical medical_review" href="/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a>.)</p><p>When PI-associated mutations do occur, they are classified as either primary (major) or secondary (minor) mutations. The mutations that emerge depend upon which medication is being administered. However, it should be emphasized that most data on mutations associated with failure of PI-based regimens come from studies of unboosted PIs, which are rarely used today. </p><p class="headingAnchor" id="H37"><span class="h3">Atazanavir</span><span class="headingEndMark"> — </span>The signature mutation associated with use of unboosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> is I50L, which does not decrease susceptibility to other PIs and, in some cases, may increase PI susceptibility. Other potential mutations include I84V and N88S.</p><p class="headingAnchor" id="H15740146"><span class="h3">Darunavir</span><span class="headingEndMark"> — </span>Pharmacologically boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> is an important agent for use in treatment-experienced patients since darunavir maintains virologic activity despite multiple PI mutations [<a href="#rid68">68</a>]. Mutations that alter the virologic response to darunavir include: 11I, L10F, V32I, L33F, I47V/A, I50V, I54L/M, G73S, T74P, L76V, V82F, I84A/C/V, L89V [<a href="#rid24">24,69</a>]. The dosing of darunavir (once versus twice daily) and the choice of boosting agent depend upon the number of PI mutations. (See  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Protease inhibitors'</a> and  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Protease inhibitors (PIs)'</a>.)</p><p>Interpreting complex genotypes can be challenging in patients with multiple PI resistance mutations. Thus, in some cases, phenotypic resistance testing may offer an advantage over genotypic testing, as it measures resistance more directly and can assess relative susceptibility and interactions among mutations. When using phenotypic assays, an optimal response to <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> is associated with a phenotypic fold change ≤10 [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays", section on 'Phenotypic resistance assays'</a>.) </p><p>In a pooled subset analysis of clinical trials comparing <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> with optimized ART in highly treatment-experienced patients, the effect of baseline susceptibility on treatment efficacy was examined [<a href="#rid68">68</a>]. Forty-seven percent of patients who had multiple mutations at baseline attained viral suppression when treated with darunavir. In addition, a prevalence study that evaluated more than 90,000 viral isolates from treatment-experienced patients found that the coexistence of three or more darunavir resistance mutations was seen at the pretreatment baseline in only 7 percent of patients [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H41"><span class="h3">Lopinavir</span><span class="headingEndMark"> — </span>Lopinavir is only available in a coformulation with <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>. Several PI mutations are required before its efficacy is significantly compromised [<a href="#rid72">72</a>]. Key mutations include L76V, V32I, I47V/A, I54L/M, V82A/F/T/S, and I84A/C/V. The primary lopinavir resistance mutation, L76V, can sensitize viral strains to <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a> [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H1854840379"><span class="h3">Tipranavir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">Tipranavir</a> is only used in heavily treatment-experienced patients and has a unique resistance profile [<a href="#rid74">74,75</a>]. As an example, the mutations I50V, I54L, and L76V, which confer significant resistance to <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, are associated with hypersusceptibility to tipranavir in vitro [<a href="#rid2">2,24,25</a>]. The use of either phenotypic resistance testing or a tipranavir mutation score [<a href="#rid76">76</a>] can be helpful in determining the use of this agent. </p><p class="headingAnchor" id="H2690793569"><span class="h3">Older, less used protease inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8634" href="/d/drug information/8634.html" rel="external">Fosamprenavir</a> – Common mutations associated with fosamprenavir, an amprenavir prodrug, include I50V and I84V. These mutations are also associated with cross-resistance to other PIs, most notably <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">Nelfinavir</a> – The signature mutation associated with nelfinavir resistance is D30N, which does not affect susceptibility to other PIs. Another less common mutation associated with nelfinavir use is L90M, which causes cross-resistance to other PIs. Nelfinavir is rarely used because of its gastrointestinal side effects (eg, diarrhea), lower efficacy, and inability to be pharmacologically boosted. (See <a class="local">'Cross-resistance'</a> above and  <a class="medical medical_review" href="/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9877" href="/d/drug information/9877.html" rel="external">Saquinavir</a> – Common mutations associated with emergence of saquinavir resistance include the unique G48V mutation, as well as the L90M mutation, which is associated with PI cross-resistance. Saquinavir is no longer a recommended drug for the treatment of HIV infection [<a href="#rid28">28,29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8558" href="/d/drug information/8558.html" rel="external">Indinavir</a> – Common mutations associated with indinavir resistance include M46/I/L, V82A/F/T, and I84V. The latter two mutations are also selected by other PIs and have a significant impact on most other PIs. This drug is no longer recommended for the treatment of HIV infection. </p><p></p><p class="headingAnchor" id="H737831544"><span class="h2">Integrase strand transfer inhibitors</span><span class="headingEndMark"> — </span>There are four integrase strand transfer inhibitors (INSTIs) approved for use: <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, and bictegravir (BIC). All of the INSTIs can be used in treatment-naïve and treatment-experienced patients, although bictegravir is only approved by the US FDA for use in combination with TAF/<a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> (FTC) as initial therapy or for use in persons with HIV who do not harbor resistance to BIC/TAF/FTC [<a href="#rid77">77</a>].</p><p>HIV-1 integrase is essential for viral replication; integrase inserts viral DNA into the cellular genome through two catalytic reactions. Loss of integrase activity disrupts the viral life cycle. Due to a different mechanism of action, there is no cross-resistance of these agents with drugs from other classes. </p><p class="headingAnchor" id="H1051732149"><span class="h3">Raltegravir and elvitegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">Raltegravir</a> and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> are INSTIs with potent in vitro activity against both wild-type and HIV isolates that are resistant to other drug classes. Both phenotypic and genotypic integrase resistance tests are commercially available. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays"</a>.) </p><p>If resistance develops, there is virtually complete cross-resistance between <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>. Signature mutations in the integrase gene associated with resistance to raltegravir include Q148H/K/R, Y143C, and N155H, which develop along three key resistance pathways. The primary mutations for elvitegravir are Q148R, E92Q, and T66l. An additional mutation at G140a/s can significantly contribute to both raltegravir and elvitegravir resistance. Additional mutations occur at codons 92, 138, and 147 [<a href="#rid78">78</a>]. </p><p>Mutations at codon 148 are associated with the highest level of integrase resistance and become more prevalent with ongoing failure. As an example, in a longitudinal analysis of a phase II study, there was a trend for the N155H mutation to be replaced by the Q148H mutation, which became predominant over time [<a href="#rid79">79</a>]. These data suggest that viruses with the Q148H mutation, in combination with other secondary mutations, have greater replicative fitness in vitro than virus with the N155H mutation [<a href="#rid80">80,81</a>]. (See <a class="local">'Replication capacity'</a> above.) </p><p class="headingAnchor" id="H1832482685"><span class="h3">Dolutegravir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">Dolutegravir</a> has a higher barrier to resistance than <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> or <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>. In addition, dolutegravir is active against raltegravir- and elvitegravir-resistant virus with Y143C- or N155H-mediated resistance. However, susceptibility is reduced in the presence of codon 148 mutations when other mutations are present. </p><p>Twice-daily dosing is recommended in patients who are INSTI-experienced if a viral isolate is found to have resistance to <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> but remains susceptible to <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, or if INSTI resistance is clinically suspected. When dosed twice daily, dolutegravir appears to have partial activity against virus with the 148 mutation [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H4124161785"><span class="h3">Bictegravir</span><span class="headingEndMark"> — </span>Bictegravir (BIC) was approved by the US FDA for use in a combination pill with TAF/FTC as an initial treatment for HIV or to replace an ART regimen in patients with suppressed viremia and no known resistance to BIC/TAF/FTC [<a href="#rid77">77,83-85</a>]. Like <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, bictegravir has a high barrier to resistance, and emergent resistance patterns have not been seen in clinical trials evaluating these patient groups [<a href="#rid83">83-87</a>]. </p><p>In vitro, mutations at positions M50I and 263K confer reduced susceptibility to bictegravir [<a href="#rid77">77</a>]. In addition, in vitro cross-resistance studies have suggested that mutations at G140A/C/S and Q148H/RK will confer reduced susceptibility to bictegravir, especially when additional INSTI mutations are present [<a href="#rid77">77,83</a>]. As bictegravir is used more broadly, a better understanding of resistance patterns should emerge. </p><p class="headingAnchor" id="H1947500410"><span class="h2">Entry inhibitors</span></p><p class="headingAnchor" id="H47"><span class="h3">CCR5 antagonists</span><span class="headingEndMark"> — </span>CCR5 antagonists, such as <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a>, are entry inhibitors. To see if maraviroc will be active, a pretreatment screening test must be utilized to assess viral tropism. (See  <a class="medical medical_review" href="/d/html/3769.html" rel="external">"Overview of HIV drug resistance testing assays", section on 'Tropism assays'</a>.)</p><p>To enter the CD4 cell, HIV requires binding to coreceptor molecules, CCR5 (by R5 viruses) or CXCR4 (by X4 viruses), in addition to attaching to the CD4 receptor. However, CCR5 antagonists are not active against viruses that enter the cell by binding to the CXCR4 receptor or viruses that enter by using both the CCR5 and CXCR4 receptor (dual or mixed tropic virus). (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'CCR5 antagonists'</a>.)</p><p>In clinical trials, virologic failure of <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a> has been attributed to the emergence of X4 viruses. The primary mechanism for this phenomenon was selection of preexisting minority populations that were not detected at baseline due to the extreme diversity of viral subpopulations in treatment-experienced patients [<a href="#rid88">88</a>]. This may be a less important problem given the improved sensitivity of available tropism assays for detecting X4 or dual/mixed tropic virus. However, even the contemporary assays can miss low frequency variants that can emerge under nonsuppressive treatment [<a href="#rid89">89</a>]. </p><p>Treatment failure can also occur as a result of emergence of <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a> resistance mutations in R5 tropic virus, but this process has not been well characterized, and resistance testing is not yet commercially available. A summary of mutations in the envelope gene associated with resistance to entry inhibitors can be found at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iasusa.org%2Fresources%2Fhiv-drug-resistance-mutations%2F&amp;token=E7Z%2Fs9z7wwGq%2BhpQ5GnDQittikdG9qKtPgjQLTll85GEDXV87h%2FzbaX3Cw8XVWHVmFDYGBBQjVSfdRGD4420mq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3772" target="_blank">IAS-USA</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=3772" target="_blank">Stanford HIV Drug Resistance Database</a> websites, which are updated regularly [<a href="#rid24">24,25</a>].</p><p>Phenotypically, resistance to CCR5 receptor antagonists manifests not as a rightward shift of the IC<sub>50</sub> curve, but as a plateau in the maximum achievable suppression of viral replication [<a href="#rid20">20</a>]. This plateau correlates with the ability of HIV to adapt to the inhibitor-bound form of CCR5 for entry [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H868647035"><span class="h3">Fusion inhibitors</span><span class="headingEndMark"> — </span>Fusion inhibitors bind to the envelope glycoprotein 41 (gp41) of HIV to prevent viral membrane fusion to the CD4 T cell membrane. The only approved fusion inhibitor is <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a> (sometimes referred to as T-20). (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Fusion inhibitors'</a>.)</p><p><a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">Enfuvirtide</a> has a low barrier to resistance. Resistance to enfuvirtide is a result of mutations occurring in a critical sequence of 10 amino acids (aa 36 to 45) within the helical region (HR-1) of gp41 envelope (<em>env</em>) gene and, to a lesser extent, in other areas of the envelope gene [<a href="#rid91">91</a>] (<a class="graphic graphic_figure graphicRef76114" href="/d/graphic/76114.html" rel="external">figure 1</a>). The substitutions most frequently associated with resistance to enfuvirtide include: G36D/S/V/E, V38A/E/M, Q40H, N42T, and N43D [<a href="#rid20">20</a>]. </p><p>Genotypic assays for <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a> resistance are commercially available. However, there are few data to guide practitioners as to whether enfuvirtide has residual activity based on these resistance mutation patterns [<a href="#rid13">13,92</a>]. Thus, it is practical to expect maximal activity with enfuvirtide when it is used for the first time; by contrast, there is likely to be minimal antiviral activity if this drug was previously utilized in a nonsuppressive regimen.</p><p class="headingAnchor" id="H2572216753"><span class="h3">Ibaluzimab</span><span class="headingEndMark"> — </span>Ibaluzimab is a humanized IgG4 monoclonal antibody that blocks the entry of HIV-1 into cells by noncompetitive binding to CD4 [<a href="#rid93">93,94</a>]. Ibaluzimab was approved by the US FDA in 2018 for use in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are failing their current antiretroviral regimen [<a href="#rid93">93</a>]. Decreased susceptibility to ibaluzimab has been described in some patients experiencing virologic failure and may be associated with genotypic changes in the HIV-1 envelope. The clinical significance of decreased susceptibility to ibaluzimab has not been fully elucidated. There is no commercial assay available to evaluate for virologic resistance to this agent in the event of virologic breakthrough on treatment.</p><p class="headingAnchor" id="H51"><span class="h1">ADDITIONAL RESOURCES</span><span class="headingEndMark"> — </span>Complex mutational patterns can be difficult to interpret. Multiple websites are available that contain comprehensive summaries of HIV-1 drug resistance mutations that are helpful to clinicians. Two of the websites are listed below [<a href="#rid95">95</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The International Antiviral Society-USA (IAS-USA) drug resistance mutation site is maintained by a group of experts that updates its summary biannually (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iasusa.org%2Fresources%2Fhiv-drug-resistance-mutations%2F&amp;token=E7Z%2Fs9z7wwGq%2BhpQ5GnDQittikdG9qKtPgjQLTll85GEDXV87h%2FzbaX3Cw8XVWHVmFDYGBBQjVSfdRGD4420mq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3772" target="_blank">www.iasusa.org/resources/hiv-drug-resistance-mutations/</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Drug Resistance Summary section of the Stanford University HIV Drug Resistance Database contains diagrammatic summaries of mutations by drug class, and provides interpretation of specific genotypes that are input by the user (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=gbrKzpZMrcLn9ZCC9ag8fFlkWQOaaRu%2BeAYLQ0lynbflPVcXgyrKCDlyBDfr3i%2Bz&amp;TOPIC_ID=3772" target="_blank">hivdb.stanford.edu</a>).</p><p></p><p class="headingAnchor" id="H52"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>With improvements in the efficacy, safety, tolerability, and convenience of antiretroviral therapy (ART), there are fewer patients with detectable viremia and resistance. Nevertheless, clinicians caring for HIV-infected patients need to understand the resistance patterns associated with specific antiretroviral medications so that they may appropriately select treatment regimens that will maximize the likelihood of viral suppression. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple factors influence the development of HIV drug resistance, including the biology of HIV, genetic barriers to resistance, regimen potency, pharmacokinetics of antiretroviral drugs, and medication adherence. Drug-resistant mutations can predate the initiation of a specific drug regimen or can develop when viral replication continues in the face of ongoing drug pressure. (See <a class="local">'Factors contributing to resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Wild-type" virus refers to the original parent virus that was predominant prior to the use of antiretroviral medications. In general, wild-type virus replicates more efficiently (ie, is more "fit") in cell culture than resistant virus and may overgrow mutant variants in the absence of drug selection pressure. (See <a class="local">'Basic terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistance testing is important to help guide treatment decisions in both treatment-naïve and treatment-experienced patients. In treatment-experienced patients with virologic failure, it is preferable to obtain resistance testing while the patient is taking antiretroviral therapy, or within weeks of discontinuing treatment, to fully assess for evidence of resistance. However, this might not be possible, as many patients with viremia are nonadherent to their regimens. (See <a class="local">'Resistance testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any nucleoside reverse transcriptase inhibitor (NRTI) can select for resistance mutations when used in a nonsuppressive regimen. In general, a single mutation can lead to resistance to <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, tenofovir, or <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, whereas resistance to <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">stavudine</a> usually requires multiple thymidine analogue mutations. (See <a class="local">'Nucleoside reverse transcriptase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The non-nucleoside reverse transcriptase inhibitors (NNRTIs) <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> have a low genetic barrier to resistance, and single mutations can eliminate antiviral activity of these drugs. <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">Doravirine</a> is a newer NNRTI, and in clinical studies, a combination of mutations (eg, at codon V106 with other known NNRTI resistance substitutions) conferred high-level resistance to the drug. <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">Etravirine</a> has a somewhat higher barrier to resistance and may be active against some efavirenz- and nevirapine-resistant isolates. (See <a class="local">'Non-nucleoside reverse transcriptase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologically boosted protease inhibitors (PIs) achieve high serum concentrations and have a high genetic barrier to resistance; therefore, decreased drug susceptibility generally requires the accumulation of multiple mutations. When boosted PIs are used by patients without preexisting PI resistance, treatment failure is rarely associated with PI resistance. (See <a class="local">'Protease inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are four integrase strand transfer inhibitors (INSTIs) available, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, and bictegravir. If integrase resistance develops, there is virtually complete cross-resistance between raltegravir and elvitegravir. Dolutegravir and bictegravir have higher barriers to resistance than raltegravir or elvitegravir. Dolutegravir can be used in treatment-experienced patients if the drug maintains activity against raltegravir- and elvitegravir-resistant virus with Y143C- or N155H-mediated resistance. However, susceptibility is reduced in the presence of codon 148 mutations when other mutations are present. (See <a class="local">'Integrase strand transfer inhibitors'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CCR5 antagonists, such as <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a>, are entry inhibitors. These agents are not active against viruses that enter the CD4 cell by binding to the CXCR4 receptor or those that enter by using both the CCR5 and the CXCR4 receptor (dual or mixed tropic virus). (See <a class="local">'Entry inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ibaluzimab is a humanized monoclonal antibody that blocks the cell entry of HIV-1 by noncompetitive binding to CD4. There is no commercially available resistance assay that can be used to evaluate the activity of ibaluzimab if virologic failure occurs while a patient is on this agent.</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Calvin J Cohen, MD, MSc, and Joel Gallant, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Feder AF, Rhee SY, Holmes SP, et al. More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. Elife 2016; 5.</a></li><li><a class="nounderline abstract_t">Llibre JM, Schapiro JM, Clotet B. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010; 50:872.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on March 01, 2020).</li><li><a class="nounderline abstract_t">Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123.</a></li><li><a class="nounderline abstract_t">Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483.</a></li><li><a class="nounderline abstract_t">Rhee SY, Sankaran K, Varghese V, et al. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol 2016; 90:6058.</a></li><li><a class="nounderline abstract_t">Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039.</a></li><li><a class="nounderline abstract_t">Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401.</a></li><li><a class="nounderline abstract_t">Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391.</a></li><li><a class="nounderline abstract_t">Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.</a></li><li><a class="nounderline abstract_t">Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696.</a></li><li><a class="nounderline abstract_t">Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223.</a></li><li><a class="nounderline abstract_t">Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007; 195:387.</a></li><li><a class="nounderline abstract_t">Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 2007; 20:550.</a></li><li><a class="nounderline abstract_t">De Luca A, Weidler J, Di Giambenedetto S, et al. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007; 45:411.</a></li><li><a class="nounderline abstract_t">Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472.</a></li><li><a class="nounderline abstract_t">Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441.</a></li><li><a class="nounderline abstract_t">Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18:1691.</a></li><li><a class="nounderline abstract_t">Shulman NS, Bosch RJ, Mellors JW, et al. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004; 18:1781.</a></li><li><a class="nounderline abstract_t">Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.</a></li><li><a class="nounderline abstract_t">Günthard HF, Calvez V, Paredes R, et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis 2019; 68:177.</a></li><li class="breakAll">United States National Institutes of Health. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Laboratory Testing, Drug-Resistance Testing. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/6/drug-resistance-testing (Accessed on August 29, 2019).</li><li><a class="nounderline abstract_t">Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356.</a></li><li class="breakAll">HIV drug resistance database. Stanford University. Available at https://hivdb.stanford.edu/ (Accessed on January 18, 2022).</li><li class="breakAll">International Antiviral Society - USA. HIV Drug Resistance Mutations Figures and User Notes. www.iasusa.org/content/drug-resistance-mutations-in-HIV (Accessed on January 02, 2018).</li><li><a class="nounderline abstract_t">Paredes R, Tzou PL, van Zyl G, et al. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One 2017; 12:e0181357.</a></li><li><a class="nounderline abstract_t">Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med 2016; 24:132.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on July 15, 2020).</li><li><a class="nounderline abstract_t">Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316:191.</a></li><li class="breakAll">World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/arv/arv-2016/en/.</li><li><a class="nounderline abstract_t">Meyer PR, Matsuura SE, Schinazi RF, et al. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44:3465.</a></li><li><a class="nounderline abstract_t">Yahi N, Tamalet C, Tourrès C, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37:4099.</a></li><li><a class="nounderline abstract_t">Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904.</a></li><li><a class="nounderline abstract_t">D'Aquila RT, International AIDS Society-USA, Schapiro JM, et al. Drug Resistance Mutations in HIV-1. Top HIV Med 2002; 10:21.</a></li><li><a class="nounderline abstract_t">Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837.</a></li><li><a class="nounderline abstract_t">Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992.</a></li><li><a class="nounderline abstract_t">De Luca A, Di Giambenedetto S, Romano L, et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193:1219.</a></li><li class="breakAll">Melby T. CNA3005: Detection of Mutations on Therapy in 3TC/ZDV+ABC Arm. 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001; Chicago, IL. Poster 448.</li><li><a class="nounderline abstract_t">Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138.</a></li><li><a class="nounderline abstract_t">Walter H, Schmidt B, Werwein M, et al. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother 2002; 46:89.</a></li><li><a class="nounderline abstract_t">Gallant JE, Gerondelis PZ, Wainberg MA, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003; 8:489.</a></li><li><a class="nounderline abstract_t">Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003; 69:1.</a></li><li><a class="nounderline abstract_t">Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 1996; 10 Suppl 5:S11.</a></li><li><a class="nounderline abstract_t">Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236.</a></li><li><a class="nounderline abstract_t">Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87.</a></li><li><a class="nounderline abstract_t">Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22.</a></li><li><a class="nounderline abstract_t">Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 2009; 199:84.</a></li><li><a class="nounderline abstract_t">Sluis-Cremer N, Sheen CW, Zelina S, et al. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007; 51:48.</a></li><li><a class="nounderline abstract_t">Rhee SY, Varghese V, Holmes SP, et al. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine 2017; 18:225.</a></li><li><a class="nounderline abstract_t">Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004; 37 Suppl 1:S36.</a></li><li><a class="nounderline abstract_t">Wirden M, Lambert-Niclot S, Marcelin AG, et al. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. AIDS 2009; 23:95.</a></li><li><a class="nounderline abstract_t">Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999; 73:8448.</a></li><li><a class="nounderline abstract_t">Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis 2019; 68:535.</a></li><li class="breakAll">Doravirine package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf.</li><li><a class="nounderline abstract_t">Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009; 48:1123.</a></li><li><a class="nounderline abstract_t">Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637.</a></li><li class="breakAll">Hellmann N, et al. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies. June 23-26, 1999. San Diego, CA. Abstract 51.</li><li><a class="nounderline abstract_t">Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835.</a></li><li><a class="nounderline abstract_t">Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.</a></li><li><a class="nounderline abstract_t">Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.</a></li><li><a class="nounderline abstract_t">Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55:600.</a></li><li><a class="nounderline abstract_t">Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18.</a></li><li><a class="nounderline abstract_t">Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011; 85:11300.</a></li><li><a class="nounderline abstract_t">Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85:11309.</a></li><li><a class="nounderline abstract_t">Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2014; 58:1652.</a></li><li><a class="nounderline abstract_t">Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010; 44:157.</a></li><li><a class="nounderline abstract_t">Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503.</a></li><li><a class="nounderline abstract_t">Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395.</a></li><li class="breakAll">US Food and Drug Administration. Product insert: Darunavir. www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf (Accessed on January 17, 2018).</li><li><a class="nounderline abstract_t">De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23:1829.</a></li><li class="breakAll">Rinehart A. Prevalence of darunavir resistance associated mutations in samples received for routine clinical resistance testing. Fifth European HIV Drug Resistance Workshop, Casais, Portugal, March 2007.</li><li class="breakAll">Danner S, et al. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 16-19, 2001. Chicago IL. Abstract 1-1925.</li><li><a class="nounderline abstract_t">Nijhuis M, Wensing AM, Bierman WF, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009; 200:698.</a></li><li><a class="nounderline abstract_t">Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179.</a></li><li><a class="nounderline abstract_t">Gathe JC Jr, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007; 23:216.</a></li><li><a class="nounderline abstract_t">Schapiro JM, Scherer J, Boucher CA, et al. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther 2010; 15:1011.</a></li><li class="breakAll">Biktarvy package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf (Accessed on February 14, 2018).</li><li><a class="nounderline abstract_t">Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82:10366.</a></li><li><a class="nounderline abstract_t">Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83:11440.</a></li><li><a class="nounderline abstract_t">Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009; 83:10245.</a></li><li><a class="nounderline abstract_t">Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010; 55:148.</a></li><li><a class="nounderline abstract_t">Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740.</a></li><li><a class="nounderline abstract_t">Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs 2018; 78:1817.</a></li><li><a class="nounderline abstract_t">Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017; 390:2073.</a></li><li><a class="nounderline abstract_t">Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017; 390:2063.</a></li><li><a class="nounderline abstract_t">Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e347.</a></li><li><a class="nounderline abstract_t">Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018; 5:e357.</a></li><li class="breakAll">Stawiski E. Coreceptor tropism predictions based on V3 loop sequence in antiretroviral experienced patients are specific but insensitive for detection of CXCR4-using variants. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2007.</li><li><a class="nounderline abstract_t">Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724.</a></li><li><a class="nounderline abstract_t">Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212.</a></li><li><a class="nounderline abstract_t">Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896.</a></li><li class="breakAll">Greenberg ML, Melby T, Sista P, et al. Baseline and On-treatment susceptibility to Enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003. Abstract 141.</li><li class="breakAll">Ibalizumab-uiyk package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf (Accessed on March 14, 2018).</li><li><a class="nounderline abstract_t">Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med 2018; 379:645.</a></li><li><a class="nounderline abstract_t">Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608.</a></li></ol></div><div id="topicVersionRevision">Topic 3772 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26882502" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158400" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158400" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7816094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824947" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099321" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087139" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16392089" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622315" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877736" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044425" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511415" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205477" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934074" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical significance of human immunodeficiency virus type 1 replication fitness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554216" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172188" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19814627" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280780" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316338" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genetic correlates of efavirenz hypersusceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18549313" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30052811" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30052811" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597449" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597449" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597449" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28753637" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28208121" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 2017 Update of the Drug Resistance Mutations in HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28208121" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2017 Update of the Drug Resistance Mutations in HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404187" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083661" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565938" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720511" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717052" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drug Resistance Mutations in HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976601" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14513419" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586357" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16586357" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377851" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antiretroviral drug resistance and resistance testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751116" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760883" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436471" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9030391" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983922" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10682153" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168738" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : K65R, TAMs and tenofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032103" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088490" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365230" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319668" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Resistance issues with new nucleoside/nucleotide backbone options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050391" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482597" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184165" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184165" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19275497" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21848464" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Development of antiretroviral drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21848464" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Development of antiretroviral drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201905" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763935" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763936" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135184" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21637112" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849444" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849432" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379202" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996323" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051805" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301557" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301557" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474650" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474650" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474650" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627247" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197808" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263650" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21041916" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21041916" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715920" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19759152" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605484" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634701" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225901" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30460547" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28867499" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28867497" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925490" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925489" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925489" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874179" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166540" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019106" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019106" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019106" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30110589" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652319" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Web resources for HIV type 1 genotypic-resistance test interpretation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
